

Table 1: Patient characteristics

	Total (N=75)	Early phase (N=18)	Late phase (N=57)	P Value
Age at ARCM diagnosis, years	59.3 ± 8.9	58.4 ± 9.2	59.6 ± 8.9	0.62
Height, cm	156.1 ± 6.0	153.8 ± 5.9	156.8 ± 5.8	0.06
Body weight, kg	55.5 ± 9.3	57.2 ± 10.5	55.0 ± 8.9	0.39
Body mass index, kg/m ²	22.8 ± 3.4	24.1 ± 3.8	22.3 ± 3.2	0.06
Total protein, g/dL	6.7 ± 0.6	6.3 ± 0.7	6.8 ± 0.6	0.012
Total cholesterol, mg/dL	191.4 ± 52.0	175.8 ± 59.7	196.1 ± 49.0	0.16
Serum creatinine, mg/dL	0.7 ± 0.5	0.6 ± 0.1	0.7 ± 0.5	0.27
Hemoglobin, g/dL	11.8 ± 1.8	11.4 ± 1.6	11.9 ± 1.8	0.37
NT-proBNP, pg/mL ^a			2014 ± 2917	
Ever smoker, n (%)	8 (10.7)	0 (0)	8 (14.0)	0.19
Hypertension, n (%)	13 (17.3)	2 (11.1)	11 (19.3)	0.72
Diabetes mellitus, n (%)	6 (8.0)	3 (16.7)	3 (5.3)	0.15
Dyslipidemia, n (%)	7 (9.3)	0 (0)	7 (12.3)	0.19
Coronary artery disease, n (%)	3 (4.0)	0 (0)	3 (5.3)	1.00

Hormone receptor

estrogen receptor, n (%)	42 (56.8)	9 (50.0)	33 (58.9)	0.59
progesterone receptor, n (%)	32 (42.7)	7 (38.9)	25 (43.9)	0.79
HER2 positivity, n (%) ^b	35 (52.2)	3 (27.3)	32 (57.1)	0.10
Triple negative	16 (21.3)	7 (38.9) ^c	9 (15.8)	0.050
Metastasis, n (%)	43 (57.3)	17 (94.4)	26 (45.6)	< 0.001
Surgery, n (%)	70 (93.3)	16 (88.9)	54 (94.7)	0.59
Radiotherapy, n (%)	46 (61.3)	11 (61.1)	35 (61.4)	1.00
Left chest radiation, n (%)	17 (22.7)	2 (11.1)	15 (26.3)	0.22

Chemotherapy agents

Doxorubicin, n (%)	40 (53.3)	13 (72.2)	27 (47.4)	0.10
Epirubicin, n (%)	37 (49.3)	7 (38.9)	30 (52.6)	0.42
Taxane, n (%)	56 (74.7)	9 (50.0)	47 (82.5)	0.011
Trastuzumab, n (%)	34 (45.3)	3 (16.7)	31 (54.4) ^d	0.006
Doxorubicin equivalent cumulative dose, mg/m ²	359 ± 198.8	525 ± 133.1	307 ± 187.6	< 0.001
Interval from the last dose to ARCM, months	28.4 ± 37.2	15.5 ± 18.8	32.5 ± 40.6	0.10
LVEF at ARCM diagnosis ^e , %	41.9 ± 7.8	43.8 ± 5.9	41.3 ± 8.2	0.23

Hospitalized HF, n (%)	29 (38.7)	8 (44.4)	21 (36.8)	0.59
Medications for HF ^f , n (%)	41 (54.7)	7 (38.9)	34 (59.6)	0.12
ACEIs or ARBs	32 (42.7)	3 (16.7)	29 (50.9)	0.014
Beta blockers	28 (37.3)	3 (16.7)	25 (43.9)	0.051
MRAs	28 (37.3)	6 (33.3)	22 (38.6)	0.78

Data are mean $\pm$ SD or n (%)

^a NT-proBNP was hardly measured in early phase, so it is not presented.

^b HER2 was not evaluated in seven cases in early phase, and one case in late phase, respectively because HER2 testing was not available. HER2-positive status refers to the strong HER2 protein expression or amplification of the HER2/neu gene, which is determined by either: an immunohistochemistry score of 3+ or a positive fluorescence in situ hybridization result.

^c Five cases were double negative in the absence of HER2 testing.

^d One out of 31 treated cases was HER2 negative: HER2 positivity with trastuzumab therapy was 3 (16.7 %) in the early phase and 30 (52.6 %) in the late phase (P=0.013).

^e Three cases (16.7 %) in the early phase and 13 (22.8 %) in the late phase was less than 35%.

^f Patients treated with ACEI, ARBs, beta blockers, or MRAs.

ACEIs, angiotensin-converting-enzyme inhibitors; ARBs, angiotensin receptor blockers; ARCM anthracycline-related cardiomyopathy; HER2, human epidermal growth factor receptor type2; HF,

heart failure; LVEF, left ventricular ejection fraction; MRAs, mineralocorticoid receptor antagonists;

NT-proBNP, N-terminal pro-brain natriuretic peptide.